A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1-Reference-Cited by-同舟云学术

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1

Published:2017-12-21 Issue:8 Volume:66 Page:1222-1229
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Huang David B¹,O’Riordan William²,Overcash J Scott²,Heller Barry³,Amin Faisal⁴,File Thomas M⁵,Wilcox Mark H⁶,Torres Antoni⁷,Dryden Matthew⁸,Holland Thomas L⁹,McLeroth Patrick¹⁰,Shukla Rajesh¹,Corey G Ralph⁹

Affiliation:

1. Motif BioSciences, New York, New York

2. eStudySites, San Diego, California

3. Long Beach Clinical Trials, Long Beach, California

4. Vohra Wound Physicians, Miramar, Florida

5. Summa Health, Akron, Ohio

6. Leeds Teaching Hospitals & University of Leeds, Leeds, United Kingdom

7. Department of Pulmonology, Hospital Clinic of Barcelona, University of Barcelona, Institut D’investigacions August Pi I Sunyer, and Centro de Investigación Biomedica En Red-Enfermedades Respiratorias, Spain

8. Department of Microbiology and Infection, Hampshire Hospitals NHS Foundation Trust, United Kingdom

9. Duke University Medical Center, Durham, North Carolina

10. Covance, Princeton, New Jersey

Funder

Motif Biosciences plc

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/66/8/1222/24595294/cix987.pdf

Reference20 articles.